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The impact of antibiotic-impregnated catheters on ventriculoperitoneal
shunt infection
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Background/aim: Ventriculoperitoneal shunt infections remain an important problem and result mainly from perioperative colonization
of shunt components by skin flora. Antibiotic-impregnated shunts have been designed to prevent such colonization. This study evaluates
the incidence of shunt infection after the insertion of antibiotic-impregnated shunts in a population of children with hydrocephalus.
Materials and methods: All pediatric patients who had undergone cerebrospinal fluid shunt insertion retrospectively were reviewed
over a 6-year period between May 2004 and December 2010. The primary outcome measure was the rate of shunt infections. Patients
were followed up with for an average of 26.2 months after shunt surgery, and shunt infections were evaluated.
Results: A total of 123 pediatric patients underwent 211 shunt placement procedures. Of these operations, 193 (91%) were performed
with nonimpregnated catheters and 18 shunts (9%) were placed with antibiotic-impregnated shunt catheters. Of the patients with
nonimpregnated catheters, 12 (6%) experienced shunt infection, whereas none of the patients with antibiotic-impregnated catheters
experienced shunt infection within the 26.2-month follow-up period (P < 0.01).
Conclusion: The antibiotic-impregnated catheters significantly reduced the incidence of shunt infection in children with hydrocephalus
during the postoperative period. Antibiotic-impregnated catheters are effective devices to prevent perioperative colonization of shunt
components.
Key words: Antibiotic-impregnated catheter, cerebrospinal fluid diversion, ventriculoperitoneal shunt infection, ventricular catheter,
ventriculoperitoneal shunt

1. Introduction
Infections due to insertion of a ventriculoperitoneal (VP)
shunt remain a most important problem and are related to
notable morbidities like mental, motor, and psychological
retardation; convulsive states; and the results of severe
infectious complications such as septicemia (1). At the
same time, some patients with central nervous system
infections require VP shunts during their illness process
(2). Shunt infections among small children and lowbirth-weight and premature infants may occur at higher
percentages than in older children. In the relevant
literature, reported infection rates range from 3% to 27%
among children implanted with a VP shunt before the age
of 6 months (3,4). Prematurity is also a risk factor for VP
shunt infections. Premature children with a birth weight of
less than 1000 g have the maximum rate of infection; the
rate of shunt infection in this group of patients is 71% (4).
Skin flora, especially gram-positive organisms, play a
major part in the developing of infections. The majority
* Correspondence: uygurer@gmail.com

of VP shunt infections take place with gram-positive
organisms accounting for over 90% of infections (5). That
the origin of the etiological microorganisms is cutaneous
flora has been shown by interim studies. They have
demonstrated that up to 80% of the etiological bacteria
come from naturally occurring cutaneous flora and are
inoculated during the shunt operation. Some other factors
such as surgical technique, duration of operation, surgeon’s
experience, and no-touch technique were studied widely
in the literature. Even with wide research into contributing
issues, very low infection rates have not been attained
constantly (6,7).
Antibiotic-impregnated shunt (AIS) catheters were
designed for prevention of VP shunt infections. AIS
catheters have been tested comprehensively in vitro before
use in a patient, showing promising sustained antibacterial
activity. In the literature, there are no uniform results
of these kinds of shunts; decisions for using them are
distinctive. Although there have been reports of the
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effect of these catheters on the infection rate in vivo, the
published data differ in their conclusions and most studies
do not report a considerable decline in infection rates (8–
10).
The aim of this study is to evaluate the incidence of
VP shunt infection after introduction of AIS catheters
in comparison with nonimpregnated catheters in a
population of children with hydrocephalus.
2. Materials and methods
2.1. Study design
Pediatric patients who had undergone cerebrospinal fluid
shunt insertion at a tertiary referral center over a 6-year
period, between May 2004 and December 2010, were
included in the study. All patients were followed for an
average of 26.2 ± 24.1 months after shunt surgery, and
shunt infections were evaluated.
All the patients had undergone the shunt procedure
under prophylactic antibiotic cover.
2.2. Diagnosis and patients
Diagnosis of hydrocephalus (HCP) was reached by
computed tomography (CT). If the ratio of frontal horn
to maximal biparietal diameter was greater than 0.3 and
there was periventricular low density on CT, the diagnosis
of HCP was accepted. Fifty percent of patients had
HCP alone, 40% had HCP with myelomeningocele, and
10% had an intracranial mass lesion with HCP. Patients
requiring revision for shunt infection had an AIS inserted.
The rest of the patients had a nonantibiotic impregnated
device inserted.
2.3. Antibiotic-impregnated shunt catheter
The Bactiseal catheter (Bactiseal Codman, Johnson
& Johnson, Boston, MA, USA), which consists of a
silicone elastomer permeated with barium, was used
as a shunt catheter. The silicone matrix is elongated
with chloroform allowing dissolution of the antibiotics
rifampicin and clindamycin, resulting in impregnation
with a concentration of 0.15% clindamycin and 0.054%
rifampicin. After inserting the catheter, the antibiotics
were released both into the catheter lumen and into
the surrounding tissue for at least a 50-day period. The
choice of antibiotics covered the most common germs
that arise in shunt infections, Staphylococcus aureus and
Staphylococcus epidermidis, which together cause around
80% of the infections.
2.4. Outcome measures
The primary outcome measure was the shunt infection
rate. VP shunt infection was diagnosed if a patient had
signs and symptoms of shunt infection with either an
organism cultured from cerebrospinal fluid or the shunt
apparatus, or a raised cerebrospinal fluid white cell count
and a clinical response to treatment for infection following
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shunt removal and appropriate antibiotic therapy.
2.5. Surgeon and operation room team
All operations were performed by the same surgeon. Only
1 assistant, 1 nurse, 1 operating room employee, and 1
anesthesiologist were found in the operating room. All
operations were performed as the first operation of the day.
2.6. Statistical analysis
Data were analyzed using the SPSS 16.0 for Windows
(SPSS Inc., Chicago, IL, USA). The results for all items were
expressed as mean ± SD, assessed within 95% reliance and
at a level of P < 0.05 significance.
3. Results
A total of 123 pediatric patients underwent 211 VP shunt
placement procedures, 55 males and 68 females (M/F =
0.8). The age of the patients was 0–192 months with a
mean of 33.6 ± 43.3 months and a median of 5 months.
The median age of the infection group was 3 months,
lower than the general patient population of this study.
The Table details the distribution of patients
having VP shunt by year of operation. The follow-up
observation period averaged 26.2 ± 24.1 months. One
hundred and ninety-three shunts (91%) were placed with
nonimpregnated catheters and 18 shunts (9%) were placed
with AIS catheters. Of the patients with nonimpregnated
catheters, 12 (6%) experienced shunt infection, whereas
none of the patients with antibiotic-impregnated catheters
experienced shunt infection within the 6-month follow-up
period (P < 0.01).
Of the 12 patients (5.7%) who became infected, 6 were
male and 6 female. The underlying condition in the infected
cases above were hydrocephalus of unknown etiology in
6 patients, meningomyelocele with hydrocephalus in 5
patients, and intracranial mass with hydrocephalus in 1
patient. Of the 12 infections, 4 occurred within 30 days
Table. The distribution of patients having ventriculoperitoneal
shunt by year of operation.
Years

Patient n (%)

2004

30 (14.2%)

2005

37 (17.5%)

2006

28 (13.4%)

2007

18 (8.5%)

2008

19 (9.0%)

2009

24 (11.4%)

2010

55 (26.0%)

Total

211 (100%)
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of the shunt procedure, which was either the primary
shunt operation or a procedure to revise the shunt. Late
infections occurred in 8 cases, about 1 month or 3 months
after shunt revision, respectively. However, no deaths
occurred as a result of shunt infection and all the patients
survived after the infected shunts were removed.
4. Discussion
In the current study we compared our experience of
AIS versus non-AIS catheter systems and demonstrated
a significant decrease in shunt infection after our
institutional conversion to AIS catheters.
Continuing HCP is another critical factor for VP shunt
infections. These infections persist to be a crucial cause of
morbidity and mortality for patients with continuing HCP
(3,6). The most susceptible group of patients for VP shunt
infections is the pediatric population. Infection rates of up
to 15% in children of less than 6 months of age have been
reported (3,4). The infection can be treated conservatively
with antibiotics, but often requires removal of the shunt.
For continuation of treatment of HCP, inserting an
extraventricular drainage system is strongly recommended.
After a suitable antibiotic treatment, insertion of a new
shunt is necessary. A prolonged stay in the hospital,
typically 1–3 weeks, is often involved. There are discrete
fiscal implications of a shunt infection, such as the hospital
stay, surgery, and implants, as well as physical, emotional,
and social costs. Efforts to confine this is an expected part
of neurosurgical practice and include meticulous operative
protocols, including duration of operative time, number
of staff in the operating suite, operating list order (earliest
on the list), surgeon supremacy, operating system (nontouch), and prophylactic antibiotics (8–10).
In a prior study it was noted that the organisms
responsible for shunt infection were infrequently detected
in the operative wound at the time of shunt insertion. The
principal authors assume that the susceptible period for
bacterial colonization of shunts may not be limited to
the operative procedure as is usually considered, but may
lengthen throughout the postoperative phase of wound
healing (11,12). The leading bacterial agent of a shunt
infection is widely accepted as Staphylococcus epidermidis,
with Staphylococcus aureus and other types of bacteria
and fungi implicated, as well. Shunt colonization with
Staphylococcus is challenging to eradicate once begun
owing to the production of biofilm (5).
AIS catheters have been used to avoid infection,
primarily in the early postoperative phase when the
largest amount of infections take place (13). On the other
hand, their clinical effectiveness in drastically reducing
shunt infections in clinical practice is doubtful and there

remains a reluctance to apply AIS catheters because of
their increased price not unavoidably translating into
obvious patient advantage (14,15). There have been several
studies with varying conclusions reported in the literature.
Govender et al.’s report is compatible with present results.
They found a significant reduction of infections with
AIS catheters, from 16.7% to 6% (8). However, they also
reported the absence of any staphylococci in any of their
AIS infections, which was in contrast to other published
reports. In a retrospective review, Sciubba et al. reported
a 2.4-fold diminished pediatric shunt infection percentage
when changing from standard to impregnated catheters
with a follow-up period of 6 months (14). A statistically
significant diminution of 6.5% to 1.2% in infection rates
has also been stated by Pattavilakom et al. (16). A singlecenter study by Eymann et al. compared 171 adults and 26
pediatric patients who had AIS catheters against 98 adults
and 22 pediatric patients who had ordinary catheters (17).
The overall infection rate dropped from 5.8% to 1% and
this was statistically significant. Kan and Kestle described
a study in children where converting from regular to AIS
catheters diminished the shunt infection rate from 8.8%
to 5.0% (10). In a similar, smaller study, Aryan et al. found
a reduction in infection rate in children from 15.2% to
3.1% (18). Richards et al. published a retrospective review
comparing AIS catheters against usual shunts (19). Their
data demonstrated a 4.7% infection rate in standard shunts
and an infection rate of 3% in AIS implantations.
The presented study has several limitations. First, it
is a retrospective study; therefore, not all the potentially
pertinent information was available to us, such as severity
of illness and duration of immunosuppression. Second,
it is a single-center study. Third, we are comparing
outcomes from different time periods. This allows the
data to be influenced by various confounding factors
and interventions that occurred during these different
time phases. Furthermore, statistically significant
conclusions would require a larger patient population
with AIS catheters. Although this study strongly suggests
an association between AIS catheter use and a decrease
in shunt infection, because of other multiple concurrent
interventions, the results should be interpreted cautiously
until a prospective study is conducted.
This study provides further evidence of the positive
effect of AIS catheters in reducing infection rates in
children with HCP. A larger group on the infection side
of this study would strengthen opinions on this topic.
Despite the significant caveats related to the study design,
we feel that the data presented can serve to guide practice
until a multiunit prospective, randomized controlled trial
provides more robust evidence.
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